4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-13-000090
$BHCCIK 0000885590operating
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 4:28 PM ET
Size
9.6 KB
Accession
0000885590-13-000090
Insider Transaction Report
Form 4
Weldon Ryan
EVP, Company Group Chairman
Transactions
- Exercise/Conversion
Common Stock, no par value
2013-10-24+15,521→ 90,590 total - Tax Payment
Common Stock, no par value
2013-10-24−8,051→ 82,539 total - Exercise/Conversion
Restricted Share Units
2013-10-24−15,521→ 0 total→ Common Stock (15,521 underlying)
Footnotes (3)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the 20 trading days starting on each measurement dates: 25% on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The maximum amount of PSUs has been achieved and paid out.
- [F2]This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1.
- [F3]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 4:28 PM ET
- Size
- 9.6 KB